Edwards Lifesciences Revises Full-Year Outlook on Higher Procedure Volumes

What happened

Edwards Lifesciences reported third-quarter net income of $307.5 million, or 53 cents a share, and revenue of $1.72 billion, up about 11%. It raised its full-year sales growth outlook to about 12% from 10% to 11%, and narrowed its adjusted earnings forecast to $2.97–$3.05 a share.

Confirmed

Global impact / market context

Higher procedure volumes are supporting sales growth, giving Edwards a basis to raise its annual outlook. If that activity continues, stronger revenue could support earnings; if procedures slow, the raised forecast may be harder to meet, affecting investor expectations for the company’s results.

Analyst inference

Quarterly revenue and adjusted earnings per share exceeded the expectations stated in the article, while net income and revenue also rose from a year earlier. The improved full-year sales outlook signals management expects procedure growth to continue, but the article gives no share-price reaction.

Confirmed

What to watch

1. Look for subsequent reports on procedure volumes: continued increases would support the higher sales-growth outlook, while slowing activity could weaken the revenue contribution from procedures. Analyst inference
2. Compare later sales growth with the roughly 12% full-year forecast; the article does not specify how much of that growth comes from procedure volumes or other factors. Analyst inference
3. Check whether adjusted earnings per share land within the revised $2.97–$3.05 range; adjusted earnings exclude certain items from the company’s reported results. Analyst inference

Evidence

• Original source link unavailable